



Attorney Docket No. 1806.1015

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	In re Patent Application of:					
	Ken SUZ	UKI				
	Application	n No.: 1	0/565,886	Group Art Unit:		
	Filed: Ja	nuary 25,	2006	Examiner:		
	For: O	XIDATION	N CATALYST			
			INFORMATION DISCLOS	SURE STATEMENT		
	PO Box 1	ioner for F 450 a, VA 223				
	Sir:					
	In accordance with the duty of disclosure provisions of 37 CFR § 1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application.					
Enclosures accompanying this Information Disclosure Statement are:						
		1a. ⊠ 1b. ⊠ 1c. ⊠ 1d. □ 1e. □ 1f. □ 1g. □	Application publications. English language copy of a co or a PCT International Search English language translation (attached to non-English languate Form PTO-1449. Explanations of Relevancy of I providing a concise explanatio List of Copending Applications	complete, Abstract or relevant portion(s)) age publications as indicated on the attached References (ATTACHMENT 1(e), hereto) for n of non-English publications.		
	2. 🛛	This Infor	mation Disclosure Statement is			
			(Check either Item 2	a or 2b or 2c or 2d)		
		2a.	Within three months of the dat § 1.491 in an international app Before the mailing of a first Of	fice Action on the merits; or fice Action after the filing of a Request for		

Serial No.: 10/565,886

3.	specified Action un	mation Disclosure Statement is filed under 37 CFR § 1.97(c) after the period in paragraph 2 above but before the mailing date of any of a Final Office der § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise osecution in the application, AND
		(Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months)
	3a.	The § 1.97(e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed.
		to be charged to Deposit Account No. 19-3935.
4.	specified	mation Disclosure Statement is filed under 37 CFR § 1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND
	4a.	The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed.
		to be charged to Deposit Account No. 19-3935.
5.	Statemen	t under § 1.97(e) (applicable if Item 3a or Item 4a is checked) (Check either Item 5a or 5b)
	5a. 🗌	In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	5b.	In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
6.	This is a (1.53(b).	continuation/divisional/continuation-in-part application under 37 CFR §
		(Check appropriate Items 6a and/or 6b)
	6a. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR § 1.98(d).
	6b. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith.

Serial No.: 10/565,886

7.		This is a	Request for Continued Examination under 37 CFR § 1.114. (Check either Item 7a or 7b)
		7a. ☐ 7b. ☐	The Issue Fee has not been paid. A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A Request for Continued Examination under 37 CFR § 1.114, after payment of the Issue Fee, is proper in accordance with 37 CFR § 1.114(a), respectively.
8.		This is a	Supplemental Information Disclosure Statement. (Check either Item 8a or 8b)
		8a. 🗌	This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can
	:	8b. 🗌	be considered as if properly filed on This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR §§ 1.97 and 1.98, mailed
9.			nce with 37 CFR § 1.98, a concise explanation of what is presently I to be the relevance of each non-English language publication is: (Check appropriate Items 9a, 9b, 9c and/or 9d)
		9a. 🗌	satisfied for the non-English language publication(s) cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of Relevance, 8th Ed., Rev. 2)
		9b. [] 9c. []	set forth in the application. satisfied for the non-English language publication(s) indicated on the attached Form PTO-1449 as having an English language translation
		9d. 🗌	(complete or relevant portion(s)) attached thereto. enclosed as Attachment 1(e), hereto.
10.	be se	e, material earch repo	on is made that the information cited in this Statement is, or is considered to to patentability nor a representation that a search has been made (other than rt(s) from a counterpart foreign application or a PCT International Search (bmitted herewith). 37 CFR §§ 1.97(g) and (h).

©2005 Staas & Halsey LLP Revised January, 2005

Serial No.: 10/565,886

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

1201 New York Ave., N.W., 7th Floor

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501

Registration No. 36,162



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.

1806.1015

10/565,886

FIRST NAMED INVENTOR

Ken SUZUKI

FILING DATE

GROUP ART UNIT

January 25, 2006

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
<u>.</u>	AC						
	AD						
	AE						
	AF						•

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	TRANSL YES	ATION NO	ABSTRACT
AG						
AL						,

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			TRANSL YES	ATION NO
	AA	Reg Davis et al., A Study of the Mechanism of Alkane Hydroxylation using the Fepy ₄ Cl ₂ -PhNHNHPh-O ₂ System, 1987, pages 425-438.		
	АВ	Ming-De Gui et al., Synthesis and Magnetic and Catalytic Properties of Manganous Isonicotinoyl Hydrazone Complexes, 1998, pages 1381-1391.		

EXAMINER	DATE CONSIDERED			
	·			
*EYAMINED: Initial if reference considered subather or not situated	Alon is in conformation with MARCH COO. Described the conformation in			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				